Drug of choice for myasthenia gravis?

Appeared in: NIMHANS Nursing Officer - 2021

Explanation

Pyridostigmine is the first-line and most commonly used drug for the symptomatic treatment of myasthenia gravis.
It is an acetylcholinesterase inhibitor, a type of indirect-acting cholinergic drug.
Its mechanism of action is to prevent the enzyme acetylcholinesterase from breaking down acetylcholine at the neuromuscular junction.
This increases the concentration and duration of action of acetylcholine, which helps to overcome the deficit of acetylcholine receptors in myasthenia gravis, thereby improving muscle strength.

Option A: Dapsone is a sulfone antibiotic and has no therapeutic effect on myasthenia gravis.
Option B: Levodopa is a dopamine precursor used to treat Parkinson's disease. It addresses a dopamine deficiency, not an acetylcholine issue.
Option C: COMT (Catechol-O-methyltransferase) inhibitors are used to treat Parkinson's disease, not myasthenia gravis. They work on the dopamine pathway.

Clinical Relevance

Nursing practice connection: Knowing Pharmacological management of Myasthenia Gravis helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
A key nursing intervention is to administer pyridostigmine 30-60 minutes before meals to maximize muscle strength for chewing and swallowing, which reduces the risk of aspiration.
Nurses must vigilantly monitor for signs of both myasthenic and cholinergic crises. While both present with weakness, the presence of excessive secretions, diarrhea, and miosis points towards a cholinergic crisis, which is a medical emergency requiring the antidote atropine.
Patient education should emphasize the importance of taking medication exactly on schedule to maintain stable blood levels and muscle strength. Missing or delaying a dose can lead to severe weakness.

How to Approach the Question

First, identify the key condition in the question stem: 'myasthenia gravis'.
Recall the basic pathophysiology of myasthenia gravis, which is an autoimmune disorder leading to a deficiency of functional acetylcholine receptors at the neuromuscular junction.
Based on the pathophysiology, determine the therapeutic goal: to increase the amount of acetylcholine available to stimulate the remaining receptors.
Analyze the options to find a drug that achieves this goal. Pyridostigmine is an acetylcholinesterase inhibitor, which directly increases acetylcholine levels.
Rule out the other options by recalling their primary indications. Dapsone is for leprosy, while Levodopa and COMT inhibitors are for Parkinson's disease, which involves dopamine deficiency.

Concept Tested & Keywords

Qg_WCaldEYlYwKNPs4-Rde

E6 Nursing Brunner Adult Health 3SA Vol 2 Part 2 p. 134-136

E6 Pharmacology Nursing Lilley 11e Part 2 p. 17-19

Practise the full NIMHANS Nursing Officer - 2021

Attempt every question from this paper in a timed mock, then review the full solution for each one.